Resources Repository
-
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Priority Setting/Ethics | Health/Medicine | Economics/Finance | Middle East & North Africa | Cost-Effectiveness Analysis | Health Systems | Sub-Saharan Africa | Latin America & Caribbean | Europe | Asia & Pacific -
ArticlePublication 2016Quality Improvement for Cardiovascular Disease Care in Low- and Middle-Income Countries: A Systematic Review
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and …
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and middle-income countries (LMICs). As part of the Disease Control Priorities Three (DCP3) Study efforts addressing quality improvement, the authors reviewed and summarized currently available evidence on interventions to improve quality of clinic-based CVD prevention and management in LMICs. Using a narrative review of published comparative clinical trials that evaluated efficacy or effectiveness of clinic-based CVD prevention and management quality improvement…
Health/Medicine | Middle East & North Africa | Health Outcomes | Evidence Synthesis | Chronic Disease/Risk | Health Systems | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Departures from Cost-Effectiveness Recommendations: Health System Constraints
Cost-effectiveness analysis assumes a single constraint, in the form of the budget constraint, whereas in reality …
Cost-effectiveness analysis assumes a single constraint, in the form of the budget constraint, whereas in reality decision makers may be faced with numerous other constraints. The objective of this article is to develop a typology of constraints that may act as barriers to implementation of cost-effectiveness recommendations. Six categories of constraints are considered: the design of the health system; costs of implementing change; system interactions between interventions; uncertainty in estimates of costs and benefits; weak governance;…
Priority Setting/Ethics | Health/Medicine | Economics/Finance | Middle East & North Africa | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Education/Labor | Government/Law | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2023Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on CEAs
This study developed and applied methods to estimate unrelated future medical costs (UFMC) for women …
This study developed and applied methods to estimate unrelated future medical costs (UFMC) for women with breast cancer in Israel and evaluated the impact of including UFMC in cost-effectiveness analyses (CEAs). Methods included a retrospective cohort study using 14 years of patient-level claims data from breast cancer patients and matched controls. UFMC were estimated through (a) the annual average all-cause healthcare costs of control subjects, and (b) predicted values from a generalized linear model (GLM)…
Health/Medicine | Middle East & North Africa | Costing Methods | Cost-Effectiveness Analysis -
ArticlePublication 2021Distributional Health and Financial Consequences of Increased Cigarette Tax in Iran: An ECEA
This study examines the potential impact of a tax-induced cigarette price increase on financial and …
This study examines the potential impact of a tax-induced cigarette price increase on financial and health outcomes across different socioeconomic groups in Iran. Using pooled cross-sectional data from Household Income and Expenditure Surveys (2002–2017) and population data from Iran in 2019, an extended cost-effectiveness analysis (ECEA) methodology is employed to model the effects of a hypothetical increase in cigarette tax. The analysis evaluates health benefits, health expenditures averted, additional tax revenues generated, changes in household…
Health/Medicine | Middle East & North Africa | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Policy/Regulation -
ArticlePublication 2016Health, Financial and Distributional Consequences of Tobacco Excise Tax in Lebanon
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes …
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes in Lebanon, a middle-income country. Extended cost-effectiveness analysis (ECEA) methods are applied to quantify, across quintiles of socio-economic status, the health benefits gained, the additional tax revenues raised, and the net financial consequences for households from a 50% increase in the price of tobacco through excise taxes. The increase in tobacco tax is estimated to result in 65,000 premature deaths…
Health/Medicine | Middle East & North Africa | Costing Methods | Cost-Effectiveness Analysis | Chronic Disease/Risk | Policy/Regulation -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Health/Medicine | Middle East & North Africa | Health Outcomes | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Global | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific